ClinicalTrials.gg
CompletedNCT06867835Updated Jan 13, 2026

Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

A Phase 4 interventional study of Vyleesi (Bremelanotide Injection) in Lactating Mother, sponsored by Cosette Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Cosette Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The primary objectives of this clinical trial performed with Vyleesi (Bremelanotide Injection) are:

  • to evaluate if Bremelanotide (BMT) is secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC.
  • to measure the concentration and characterize the pharmacokinetics of BMT secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC.

This open-label, pharmacokinetic (PK) study will be performed in 10 healthy lactating female subjects between 10 days and 6 months post-partum (inclusive). The maximum duration of subject participation in the study will be approximately 29 days, consisting of 3-week Screening period, a 1 day treatment period, and up to a 7 day follow-up period.

02

Conditions studied

  • Lactating Mother
03

In context

Lead sponsor

This is the only study on the registry with Cosette Pharmaceuticals, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects ≥18 to 55 years of age (inclusive) and premenopausal
  • Lactating, between 10 days and 6 months postpartum (inclusive).
  • Exclusively breastfeeds their infant prior to participation in the study
  • Is willing to pump and store breastmilk for feeding her infant for a minimum of 48 hours in advance of study initiation and discontinue breastfeeding their infant for the duration of their study participation (beginning from time of dosing with BMT) and a minimum of 24 hours following the Safety Follow-Up visit (i.e., a minimum of 48 hours following dosing with BMT).
  • Ensure at the time of screening that the breastfed infant can feed from a bottle during maternal participation in the study
  • The subject is not pregnant, and does not intend to become pregnant before, during, or within 1 complete menstrual cycle or 2 months after administration of study drug
  • Subjects of who are sexually active with a nonsterilized male partner must have stable, continuous use of an acceptable method of throughout the duration of the study, and for at least 60 days after the dose of study drug

Exclusion criteria

Exclusion Criteria (Main Criteria):

  • Breastfeeding is not well established in the mother-infant pair (e.g., poor latching of the infant or low milk supply).
  • Any condition that interferes with the successful collection of milk from one or both breasts including but not limited to lactation mastitis (typically presents as a tender, hot, swollen area of the breast that may or may not involve an infection), milk blister that may present as a blocked nipple pore, breast abscess, etc.
  • Has used any compound and/or an experimental medical device within 28 days before Screening.
  • Has taken BMT within 24 hours of participation in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Vyleesi

    One dose of BMT 1.75 mg SC on Day 1

    Drug: Vyleesi (Bremelanotide Injection)

Interventions

06

What researchers measure

Primary outcomes

  1. Levels of Bremelanotide (BMT) in Breast Milk Over 24h After Administration of Vyleesi

    The levels/concentrations of bremelanotide (BMT) will be measured in breast milk samples collected at different timepoints up to 24h from lactating women who receive a single dose of Vyleesi (BMT 1.75 mg SC).

    Time frame: 24 hours

  2. Area under the curve from time 0 to end of dosing interval (AUCtau) for BMT in Breast Milk

    Time frame: 24 hours

  3. Maximum observed concentration (Cmax) of BMT in breast milk

    Time frame: 24 hours

  4. Time to reach Cmax of BMT in breast milk (Tmax)

    Time frame: 24 hours

  5. Terminal half-life of BMT in breast milk (t1/2)

    Time frame: 24 hours

Secondary outcomes

  1. Levels of Bremelanotide (BMT) in Plasma Over 24h After Administration of Vyleesi

    Time frame: 24 hours

  2. Area under the curve from time 0 to end of dosing interval (AUCtau) for BMT in Plasma

    Time frame: 24 hours

  3. Maximum observed concentration (Cmax) of BMT in Plasma

    Time frame: 24 hours

  4. Time to reach Cmax of BMT in Plasma (Tmax)

    Time frame: 24 hours

  5. Milk:plasma ratio (M/P) of BMT Levels

    Time frame: 24 hours

07

Study locations

1 site
  • First Excellence Research Group LLC
    Doral, Florida 33178, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Nov 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Mar 10, 2025
StartActual
Jul 11, 2025
Primary completionActual
Nov 15, 2025
CompletionActual
Nov 15, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06867835
Lead sponsor
Cosette Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Jul 11, 2025
Primary completion
Nov 15, 2025
Completion
Nov 15, 2025
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion